Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715285 | 0.89 | PARP1 (0.46) | PARP1PARP10PARP11PDPK1 | |
| SCHEMBL2223651 | 0.80 | CA12 (0.50) | PARP1PARP10PARP11PDPK1CYP1A2 | |
| SCHEMBL30975576 | 0.77 | TDP2 (0.41) | PARP1PARP10PARP11PDPK1CYP1A2 | |
| SCHEMBL5235719 | 0.77 | TDP2 (0.37) | PARP1PARP10PARP11PDPK1CYP1A2 | |
| SCHEMBL699878 | 0.74 | CYP1A2 (0.58) | PARP1PARP10PARP11PDPK1CYP1A2 | |
| SCHEMBL22579802 | 0.74 | TDP1 (0.42) | — | |
| SCHEMBL4015467 | 0.74 | TDP2 (0.45) | GRM5CYP1A2 | |
| SCHEMBL29807425 | 0.74 | TDP2 (0.45) | GRM5CYP1A2 | |
| SCHEMBL4670599 | 0.72 | TDP2 (0.39) | CYP1A2 | |
| SCHEMBL299769 | 0.72 | TDP2 (0.52) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | claimed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | claimed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | claimed |
| US-5391554-A | Antitumor agent | WARNER-LAMBERT COMPANY (US) | 1995-02-21 | — | — | US | claimed |
| WO-1994005664-A1 | NAPHTHYRIDINES AS POTENTIATORS OF LETHAL EFFECTS OF RADIATION ON TUMOUR CELLS | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | claimed |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20090149492-A1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-11 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2008064107-A2 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| US-5391554-A | Antitumor agent | WARNER-LAMBERT COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| WO-1994005664-A1 | NAPHTHYRIDINES AS POTENTIATORS OF LETHAL EFFECTS OF RADIATION ON TUMOUR CELLS | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | PARP1 1482/4885PARP10 491/4885PARP11 579/4885 |
| US-20090149492-A1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | DPP4, DPP7, DPP8 | PARP1 2185/4885PARP10 2861/4885PARP11 1816/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | PARP1 205/4885PARP10 58/4885PARP11 63/4885 |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885PARP10 15/4885PARP11 7/4885 |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | PARP1 351/4885PARP10 120/4885PARP11 119/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | PARP1 2689/4885PARP10 2059/4885PARP11 1706/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | PARP1 1538/4885PARP10 427/4885PARP11 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.